Section Ph 703.03 - Prescriptions(a) All schedule III through V controlled substance prescription drug orders, as described in RSA 318-B:1-b, and transmitted by facsimile or as an electronic prescription, shall include: (1) The name and address of the patient;(2) The name, strength, and quantity of the drug prescribed;(3) Any directions specified by the prescribing practitioner;(4) The full name of the prescribing practitioner which shall be printed, rubber stamped, or typewritten above or below his or her handwritten signature;(5) The address of the prescribing practitioner;(6) The federal drug enforcement administration (DEA) number assigned to the prescribing practitioner; and(7) The date the prescription was ordered.(b) A facsimile prescription for a schedule II controlled substance shall not be accepted as an original written prescription except in circumstances when:(1) A prescription prepared in accordance with RSA 318-B:9, III and IV, and issued for a schedule II substance, as described in RSA 318-B:1-b, to be compounded for the direct administration, to a patient in a private residence, long-term care facility, or hospice setting, by parenteral, intravenous, intramuscular, subcutaneous, oral administration, or intraspinal infusion. The printed copy of the transmission shall serve as the original written prescription and shall be maintained in accordance with the provisions of RSA 318-B:9, I; and(2) A prescription prepared in accordance with RSA 318-B:9, III and IV, and issued for a schedule II substance, as described in RSA 318-B:1-b, for a resident of a long-term care facility or patient enrolling in hospice care program. Such prescriptions may be transmitted by the practitioner or the practitioner's designated agent, to the dispensing pharmacy. The printed copy of the transmission shall serve as the original written prescription and shall be maintained in accordance with the provisions of RSA 318-B:9, I; and(c) The pharmacist shall exercise professional judgment regarding the accuracy and authenticity of the transmitted prescription drug order which shall be consistent with existing federal or state laws and rules.(d) For controlled substances in schedules II, III, IV, or V, as described in RSA 318-B:1-b, a pharmacy may receive an electronically transmitted drug order from the prescriber for filling provided that it is transmitted in accordance with federal law with an electronic signature meeting security requirements required by the Drug Enforcement Agency (DEA) for electronic prescriptions.(e) All prescriptions dispensed by a health care provider or pharmacy containing an opiate shall: (1) Affix an orange sticker to the cap or dispensing device with the word "opioid" in easily legible font;(2) Have a warning label that states "Risk of Addiction or Overdose"; and(3) Provide the person with handout provided by the governor's commission on alcohol and drug abuse, prevention, treatment, and recovery on guidance for associated risks of opioid use and how to mitigate them.(f) Pharmacists or a pharmacy that dispenses a drug containing an opioid that is to be administered to a patient treated in a health care facility required to be licensed under RSA 151 shall not be subject to the provisions of (e) above.(g) Failure to comply with Ph 703.02 shall result in disciplinary action by the board.N.H. Admin. Code § Ph 703.03
#1639, eff 11-1-80; ss by #2260, eff 1-5-83; ss by #2914, eff 11-27-84; ss by #4600, eff 8-1-89; ss by #6094-B, INTERIM, eff 9-21-95, EXPIRED, 1-19-96
New. #6181-B, eff 2-5-96, EXPIRED: 2-5-04
New. #8316, eff 3-26-05
Amended by Volume XXXV, Number 32 Filed August 13, 2015, Proposed by #10903, Effective 8/5/2015, Expires8/5/2025.Amended by Volume XLII Number 28, Filed July 14, 2022, Proposed by #13398, Effective 6/16/2022, Expires 6/16/2032